GENE202 is a single dose gene therapy for patients with rare metabolic disease, methylmalonic acidaemia.

Merck’s MRK stock has risen 32.3% in the past three months. The stock has also been trading above its 50-day and 200-day ...

The University of Auckland is hosting the research as part of the Global COVID Vaccine Safety (GCoVS) Project. Scientists ...

The FDA has directed pharma companies of influenza vaccines to update their product labelling to include the risk of ...

The cell and gene therapy sector has never lacked attention, but all too often, the narrative swings from one extreme to ...

The vaccines subsector received a big fillip from Covid, but its potential extends far beyond combating pandemics. Here's what it means for investors ...

Accomplished RNA therapeutics leader with track record of advancing novel genetic medicines from discovery to FDA approval to lead research and development at FlashpointEVANSTON, Ill.--(BUSINESS WIRE) ...

China has rapidly become a leading hub for innovative new medicines, overtaking Europe and putting the continent at risk of ...

Secretary Robert F. Kennedy Jr. has dismissed at least four of the Advisory Commission on Childhood Vaccines (ACCV) before ...

AstraZeneca had already bagged the rights to the AbelZeta Pharma-partnered CAR-T cell therapy for most of the world. | The ...

By Maggie Fick SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on ...

AstraZeneca plans to delist from Nasdaq and move to the NYSE, while its breast cancer drug Enhertu enters European regulatory review after strong trial results.